SLRX 8-K: Hogan Lovells legal opinion attached as Exhibit 5.1

Rhea-AI Filing Summary

Salarius Pharmaceuticals, Inc. filed a Current Report on Form 8-K dated August 22, 2025 noting that, in connection with a Prospectus Supplement, the company is submitting a legal opinion from Hogan Lovells US LLP concerning the validity of the shares being registered. That legal opinion is attached as Exhibit 5.1 and is incorporated by reference under Item 9.01 (Financial Statements and Exhibits).

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

0001615219FALSE2450 Holcombe Blvd.Suite XHoustonTX00016152192025-08-152025-08-15

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 22, 2025

SALARIUS PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)

Delaware

001-36812

46-5087339

(State or other jurisdiction of incorporation)

(Commission File Number)

(IRS Employer Identification Number)

2450 Holcombe Blvd. Suite X Houston, TX

77021

(Address of principal executive offices)

(Zip Code)

(713) 913-5608
(Registrant’s telephone number, including area code)

N/A
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:

Title of each class						Trading Symbol(s)			Name of each exchange on which registered
Common Stock, par value $0.0001						SLRX			The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐

Item 8.01. Other Events.

On August 22, 2025, Salarius Pharmaceuticals, Inc. (the “Company”) filed a prospectus supplement (the “Prospectus Supplement”) to its effective registration statement on Form S-3 (File No. 333-266589) (the “Registration Statement”), filed with the U.S. Securities and Exchange Commission on August 5, 2022 and declared effective by the SEC on August 16, 2022, covering the registered offering of up to $2,600,000 of shares of common stock, par value $0.0001 per share, of the Company (the “Shares”), pursuant to the At the Market Offering Agreement, dated as of February 5, 2021, with Ladenburg Thalmann & Co. Inc.

In connection with the filing of the Prospectus Supplement, the Company is filing a legal opinion of its counsel, Hogan Lovells US LLP, relating to the validity of the Shares being registered, which opinion is attached as Exhibit 5.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.

Description

5.1

Opinion of Hogan Lovells US LLP

23.1

Consent of Hogan Lovells US LLP (included in Exhibit 5.1)

104

Cover Page Interactive Data File (embedded within the inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SALARIUS PHARMACEUTICALS, INC.

Date: August 26, 2025

By:

/s/ Mark J. Rosenblum

Mark J. Rosenblum Acting Chief Executive Officer, Executive Vice President & Chief Financial Officer

FAQ

What did Salarius Pharmaceuticals (SLRX) file on August 22, 2025?

The company filed a Form 8-K stating it attached a Hogan Lovells legal opinion as Exhibit 5.1 concerning the validity of the shares being registered in connection with a Prospectus Supplement.

What is Exhibit 5.1 in the Salarius 8-K (SLRX)?

Exhibit 5.1 is the legal opinion from Hogan Lovells US LLP regarding the legal validity of the shares being registered, and it is incorporated by reference into Item 9.01.

Does the filing state any financial results or transactions for SLRX?

No. The filing only references the legal opinion attached as Exhibit 5.1 and does not disclose financial results, transactions, or earnings data.

Is there an indication in the filing about emerging growth company status?

The document includes a checkbox line for emerging growth company status ("If an emerging growth company, indicate by check mark…"). No checked selection or further statement of status is provided in the disclosed text.

Where in the 8-K is the exhibit listed?

The filing lists the legal opinion under Item 9.01 (Financial Statements and Exhibits) and identifies it specifically as Exhibit 5.1.